Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SAB Biotherapeutics, Inc. - Common Stock (NQ:SABS)

2.160 +0.140 (+6.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SAB Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
SAB BIO Announces Oversubscribed $175 Million Private Placement
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Why Is SAB BIO Stock Trading Lower On Tuesday?
SAB BIO's SAB-142 Phase 1 trial data supports its safety and pharmacodynamic activity, paving the way for a Phase 2b trial in T1D in 2025. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Gold Gains 1%; Boeing Shares Rise Following Q4 Results
 
Via Benzinga
Nasdaq Surges More Than 300 Points; Lockheed Martin Shares Dip After Q4 Results
 
Via Benzinga
Dow Gains Over 50 Points; General Motors Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Reports Full Year 2024 Operating and Financial Results
SAB-142 Phase 1 trial positive topline data announced at KOL event 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO to Participate in Upcoming Investor Conferences
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
Investor webinar scheduled Tuesday, January 28, 2025, at 8:00 AM EST 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SABS Stock Earnings: SAB Biotherapeutics Beats EPS for Q2 2024
SABS stock results show that SAB Biotherapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
SAB BIO Appoints Lucy To as Chief Financial Officer
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAb Biotherapeutics Rebrands as SAB BIO
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback